After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against recommendations.

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its affiliated hospitals.

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.

As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.